3.8 Review

Bryostatin-1: Pharmacology and therapeutic potential as a CNS drug

Journal

CNS DRUG REVIEWS
Volume 12, Issue 1, Pages 1-8

Publisher

WILEY
DOI: 10.1111/j.1527-3458.2006.00001.x

Keywords

Alzheimer's disease; antidepressants; bryostatin-1; cognition activation; depression; learning and memory; mood; protein kinase C

Ask authors/readers for more resources

Bryostatin-1 is a powerful protein kinase C (PKC) agonist, activating PKC isozymes at nanomolar concentrations. Pharmacological studies of bryostatin-1 have mainly been focused on its action in preventing tumor growth. Emerging evidence suggests, however, that bryostatin-1 exhibits additional important pharmacological activities. In preclinical studies bryostatin-1 has been shown at appropriate doses to have cognitive restorative and antidepressant effects. The underlying pharmacological mechanisms may involve an activation of PKC isozymes, induction of synthesis of proteins required for long-term memory, restoration of stress-evoked inhibition of PKC activity, and reduction of neurotoxic amyloid accumulation and tau protein hyperphosphorylation. The therapeutic potential of bryostatin-1 as a CNS drug should be further explored.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available